APA (7th ed.) Citation

Niger, M., Nichetti, F., Fornaro, L., Pircher, C., Morano, F., Palermo, F., . . . Mazzaferro, V. (2024). A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study. BMC.

Chicago Style (17th ed.) Citation

Niger, Monica, et al. A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study. BMC, 2024.

MLA (9th ed.) Citation

Niger, Monica, et al. A Phase II/III Randomized Clinical Trial of CisPlatin PlUs Gemcitabine and Nabpaclitaxel (GAP) as PReoperative Chemotherapy Versus Immediate Resection in PatIents with ResecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence: PURITY Study. BMC, 2024.